In addition, RAF265 (III) (PDB ID: 5CT7) (Fig. 2) is a potent dual BRAF/VEGFR-2 inhibitor that showed a potent activity against melanoma and colorectal cancer [39, 40]. Here, KDR is linked to melanoma.